The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
Official Title: Phase II Study of Irinotecan, Carboplatin, and Sunitinib in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer
Study ID: NCT00695292
Brief Summary: This proposed Phase II trial will investigate the combination of irinotecan and carboplatin followed by sunitinib in the first-line treatment of patients with extensive-stage SCLC.
Detailed Description: Irinotecan/platinum regimens are emerging as standard treatments for patients with extensive-stage disease. The irinotecan/carboplatin doses that will be used in this study have been used in two previous Phase II SCLC trials, and were found to be extremely well tolerated (Thompson et al. 2005; Spigel et al. 2007). Adding a novel, minimally toxic agent to this regimen may further enhance efficacy in this patient population without contributing to toxicity. This trial will evaluate the use of sunitinib following 6 cycles of treatment with chemotherapy in the treatment of SCLC. The trial will be performed under the leadership of SCRI, a community-based, multi-center, clinical trial organization.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Florida Cancer Specialists, Fort Myers, Florida, United States
Florida Hospital Cancer Insitute, Orlando, Florida, United States
Northeast Georgia Medical Center, Gainesville, Georgia, United States
Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
St. Louis Cancer Care, Chesterfield, Missouri, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Tennessee Oncology, Nashville, Tennessee, United States
Name: David R Spigel, M.D.
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR